Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
This article was originally published in The Pink Sheet Daily
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.
You may also be interested in...
US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.
Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.